EMA: TTIP and inspection databases a way of improving global manufacturing standards

By Gareth Macdonald

- Last updated on GMT

Related tags International trade Pharmaceutical industry

EMA to focus on supply chains and using trade deals to push standards
EMA to focus on supply chains and using trade deals to push standards
Ensuring drugs, APIs and excipients are safe will be a focus for the EMA, which says it will explore supplier inspection databases and using trade deals like TTIP to promote GMP standards globally.

The European regulator outlined its network 2020​ strategy today, explaining it plans to work with national drug agencies to oversee pharmaceutical supply chains in a bid to eliminate duplicate inspections.

The EMA said: “The complexity of international supply chains present risks of errors and occasionally counterfeits or product diversion​” adding that it is vital all steps in the supply chain are adequately controlled and monitored.

Sharing of information between regulators responsible for oversight of different manufacturing stages and ensuring that the same standards are applied irrespective of manufacturing location will help minimise possible problems​.”

The agency said it will also work to make sure drug and ingredient quality data is accurate, explaining that: “The integrity of the data in the studies used to support market authorisation is fundamental to trust and confidence in the products themselves.

The network will work with global partners to address the challenges posed by increasingly complex supply chains, global industries and falsified and counterfeit medicines​” the EMA said, citing supplier identification and databases as areas that will be “explored​.”

Trade deal quality

The EMA stressed the importance of working with the World Health Organisation (WHO) to drive convergence of manufacturing standards around the world, particularly in key supply hubs like India and China.

The agency also suggests international trade agreements – TTIP​, CETA​ and free trade agreements with Japan and Singapore – provide a way of promoting European good manufacturing practices (GMP) and distribution standards.

“The network will explore the opportunities presented by draft trade agreements and other mechanisms to promote greater mutual reliance on inspection outcomes in both, human and veterinary medicines” it said, adding that strengthening mutual reliance agreements will help it make best use of resources.

The agency gave the example of generic drugs as one area in which collaboration is likely, citing information sharing pilot programmes​ as areas of expansion.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) told us it is still reviewing the EMA strategy document.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more